Effectiveness of 12 or 24 week LDV/SOF and 12 week LDV/SOF plus RBV in treatment-experienced patients with cirrhotic, genotype 1 Hepatitis C: Real-world experience from the TRIO Network

被引：0
|
作者：
Curry, Michael P. [1 ]
Bacon, Bruce [2 ]
Flamm, Steven L. [3 ]
Kowdley, Kris V. [4 ]
Dieterich, Douglas [5 ]
Milligan, Scott [6 ]
Tsai, Naoky C. S. C. [7 ]
机构：
[1] Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA
[2] St Louis Univ, Sch Med, St Louis, MO USA
[3] Northwestern Feinberg Sch Med, Chicago, IL USA
[4] Swedish Med Ctr, Liver Care Network, Seattle, WA USA
[5] Icahn Sch Med Mt Sinai, New York, NY 10029 USA
[6] Trio Hlth Analyt, Newton, MA USA
[7] Univ Hawaii, Queens Med Ctr, Honolulu, HI 96822 USA
来源：
HEPATOLOGY | 2015年 / 62卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
1108
引用
收藏
页码：755A / 755A
页数：1
相关论文
共 50 条
  • [31] Final Evaluation of 955 HCV Patients Treated With 12 Week Regimens Containing Sofosbuvir plus /- Simeprevir in the TRIO Network: Academic and Community Treatment of a Real-World, Heterogeneous Population
    Dieterich, Douglas T.
    Bacon, Bruce
    Flamm, Steven L.
    Kowdley, Kris
    Milligan, Scott
    Tsai, Naoky
    Younossi, Zobair M.
    Lawitz, Eric
    [J]. GASTROENTEROLOGY, 2015, 148 (04) : S1001 - S1001
  • [32] FINAL EVALUATION OF 955 HCV PATIENTS TREATED WITH 12 WEEK REGIMENS CONTAINING SOFOSBUVIR plus /- SIMEPREVIR IN THE TRIO NETWORK: ACADEMIC AND COMMUNITY TREATMENT OF A REAL-WORLD, HETEROGENEOUS POPULATION
    Dieterich, D.
    Bacon, B.
    Flamm, S.
    Kowdley, K.
    Milligan, S.
    Tsai, N.
    Younossi, Z.
    Lawitz, E.
    [J]. JOURNAL OF HEPATOLOGY, 2015, 62 : S621 - S621
  • [33] Elbasvir/Grazoprevir effectiveness in patients with Chronic Hepatitis C and Chronic Kidney Disease: real-world experience from the TRIO Network
    Younossi, Z.
    Bacon, B.
    Curry, M.
    Dieterich, D.
    Flamm, S.
    Kowdley, K.
    Milligan, S.
    Nwankwo, C.
    Tsai, N.
    Afdhal, N.
    [J]. JOURNAL OF HEPATOLOGY, 2017, 66 (01) : S748 - S749
  • [34] High real-world effectiveness of 12-week elbasvir/grazoprevir without resistance testing in the treatment of patients with HCV genotype 1a infection in Norway
    Leiva, Rafael A.
    Bergersen, Bente M.
    Finbraten, Ane-Kristine
    Sandvei, Per Kristian
    Simonsen, Oystein
    Rosseland, Carola M.
    Hagen, Karin
    Young, Lital
    Roberts, R. Scott
    Mikkelsen, Yngve
    Singh, Ravinder
    Lagging, Martin
    Dalgard, Olav
    [J]. SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY, 2023, 58 (03) : 264 - 268
  • [35] Simeprevir (SMV) and Sofosbuvir (SOF) Without Ribavirin (RBV) for 12 Weeks for Genotype 1 Chronic Hepatitis C (CHC-1) With and Without Hepatic Decompensation: A Real-Life Single-Center Experience
    Lutchman, Glen
    Nghia Nguyen
    Chang, Christine Y.
    Ahmed, Aijaz
    Daugherty, Tami
    Garcia, Gabriel
    Kumari, Radhika
    Kim, W. Ray
    Gupta, Soumi
    Doshi, Dilesh
    Nguyen, Mindie H.
    [J]. GASTROENTEROLOGY, 2015, 148 (04) : S1089 - S1089
  • [36] The Impact of Concomitant Acid Reducing Therapy (ART) on Sustained Virologic Response (SVR-12) Among Genotype 1 Infected Chronic Hepatitis C (CHC) Patients Treated with Ledipasvir/Sofosbuvir (LDV/SOF) With or Without Ribavirin
    Spoutz, Patrick
    Schaefer, Monica
    Pandya, Prashant K.
    Patterson, Mark
    [J]. HEPATOLOGY, 2016, 64 : 477A - 478A
  • [37] Efficacy of 8-versus 12-week treatment with ledipasvir/sofosbuvir in chronic hepatitis C patients eligible for 8-week regimen in a real-world setting
    Zarebska-Michaluk, Dorota
    Piekarska, Anna
    Jaroszewicz, Jerzy
    Klapaczynski, Jakub
    Sitko, Marek
    Tudrujek-Zdunek, Magdalena
    Tomasiewicz, Krzysztof
    Belica-Wdowik, Teresa
    Pabjan, Pawel
    Lorenc, Beata
    Czauz-Andrzejuk, Agnieszka
    Tronina, Olga
    Krygier, Rafal
    Dobracki, Witold
    Buczynska, Iwona
    Simon, Krzysztof A.
    Dybowska, Dorota
    Halota, Waldemar
    Pawlowska, Malgorzata
    Citko, Jolanta
    Laurans, Lukasz
    Mazur, Wlodzimierz
    Janczewska, Ewa
    Socha, Lukasz
    Deron, Zbigniew
    Berak, Hanna
    Flisiak, Robert
    [J]. ARCHIVES OF MEDICAL SCIENCE, 2022, 18 (06) : 1460 - 1466
  • [38] Effectiveness of 8-or 12-weeks of ledipasvir and sofosbuvir in real-world treatment-naive, genotype 1 hepatitis C infected patients
    Curry, M. P.
    Tapper, E. B.
    Bacon, B.
    Dieterich, D.
    Flamm, S. L.
    Guest, L.
    Kowdley, K. V.
    Lee, Y.
    Milligan, S.
    Tsai, N.
    Younossi, Z.
    Afdhal, N. H.
    [J]. ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2017, 46 (05) : 540 - 548
  • [39] Real-world experience of 12-week direct-acting antiviral regimen of glecaprevir and pibrentasvir in patients with chronic hepatitis C virus infection
    Toyoda, Hidenori
    Atsukawa, Masanori
    Watanabe, Tsunamasa
    Nakamuta, Makoto
    Uojima, Haruki
    Nozaki, Akito
    Takaguchi, Koichi
    Fujioka, Shinichi
    Iio, Etsuko
    Shima, Toshihide
    Akahane, Takehiro
    Fukunishi, Shinya
    Asano, Toru
    Michitaka, Kojiro
    Tsuji, Kunihiko
    Abe, Hiroshi
    Mikami, Shigeru
    Okubo, Hironao
    Okubo, Tomomi
    Shimada, Noritomo
    Ishikawa, Toru
    Moriya, Akio
    Tani, Joji
    Morishita, Asahiro
    Ogawa, Chikara
    Tachi, Yoshihiko
    Ikeda, Hiroki
    Yamashita, Naoki
    Yasuda, Satoshi
    Chuma, Makoto
    Tsutsui, Akemi
    Hiraoka, Atsushi
    Ikegami, Tadashi
    Genda, Takuya
    Tsubota, Akihito
    Masaki, Tsutomu
    Tanaka, Yasuhito
    Iwakiri, Katsuhiko
    Kumada, Takashi
    [J]. JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2020, 35 (05) : 855 - 861
  • [40] Single-Center Real-World Experience of Sofosbuvir Plus Simeprevir for 12 Weeks for Genotype 1 Chronic Hepatitis C With Advanced Fibrosis
    Lebovics, Edward
    Maranino, Ashley N.
    Zahiruddin, Ayesha
    Gupta, Nancy
    Frenkel, Jerry
    Lebovics, Nachum
    Casellas, Ana
    Hirsch, Jody
    [J]. GASTROENTEROLOGY, 2015, 148 (04) : S1084 - S1084
12345